ImmunoCellular Therapeutics Expands Manufacturing Relationship with Neostem's Progenitor Cell Therapy

ImmunoCellular Therapeutics

announced the expansion of its relationship with Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc.

, for current good manufacturing practices (cGMP) services for ImmunoCellular's dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a phase I clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a Services Agreement between the companies. PCT also manufactured phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM. Under this newly executed Services Agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT